Dr. Reddy’s Laboratories Ltd ADR
NYSE: RDY
$13.99
-$0.31 (-2.2%)
Closing Price on November 21, 2024
RDY Stock Chart and Intraday Price
RDY Stock Data
| Asset Type | Common Stock |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 8-2-337, ROAD NO.3 BANJARA HILLS, HYDERABAD, IN |
| Fiscal Year End | March |
| Latest Quarter | 2023-12-31 |
| Market Cap | 12,278.36M USD |
| Shares Outstanding | 166,522,000 |
RDY Articles
Here is a look at why companies split their stocks and why stock splits matter. Plus, upcoming stock splits to watch from Dr. Reddy's Laboratories, Southern Copper, and more.
Published:
24/7 Wall St. is looking at some big analyst calls that we have seen so far on Tuesday, including Allstate, Electronic Arts and Zillow.
Published:
Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
Published:
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
Published:
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
Published:
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Published:
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Published:
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
Published:
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
Published:
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Published:
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
Published:
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
Published:
Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica, Marvell Technology,...
Published:
Last Updated:
India has been one of the best growth economies measured by gross domestic product for some time, but the secular growth opportunity has faced multiple setbacks in 2018 that may persist,
Published:
Last Updated:
Everyone knows that investors will pay up to chase growth, and it is quite possible that India might be one of the best growth stories in the world for 2018 and beyond.
Published:
Last Updated: